Kamada Ltd. (KMDA)

Market Cap	214.32M
Revenue (ttm)	131.96M
Net Income (ttm)	-2.30M
Shares Out	44.84M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	10.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,801
Open	4.72
Previous Close	4.72
Day's Range	4.70 - 4.78
52-Week Range	3.72 - 5.72
Beta	0.24
Analysts	Strong Buy
Price Target	11.00 (+130.66%)
Earnings Date	May 24, 2023

About KMDA

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varice...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 380
• Stock Exchange: NASDAQ
• Ticker Symbol: KMDA

Financial Performance

In 2022, Kamada's revenue was $129.34 million, an increase of 24.79% compared to the previous year's $103.64 million. Losses were -$2.32 million, 4.08% more than in 2021.

Analyst Forecast

According to one analyst, the rating for KMDA stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(130.66% upside)

Analyst Consensus: Strong Buy